Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20235103 | 0.86 | HRH3 (0.54) | HRH3KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL20330408 | 0.82 | HRH3 (0.55) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16437255 | 0.81 | HRH3 (0.56) | HRH3KDM4EALDH1A1DRD2MAPT | |
| SCHEMBL20314567 | 0.80 | HRH3 (0.55) | HRH3KDM4EALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL9628483 | 0.78 | HRH3 (0.52) | HRH3DRD2DRD4MAPT | |
| SCHEMBL18591747 | 0.78 | DRD4 (0.41) | HRH3ALDH1A1DRD2DRD4MAPT | |
| SCHEMBL20235102 | 0.78 | HRH3 (0.63) | HRH3KDM4EDRD2 | |
| SCHEMBL271336 | 0.76 | DRD2 (0.64) | HRH3KDM4ESMN1; SMN2DRD2DRD4 | |
| SCHEMBL23664607 | 0.76 | NCF1 (0.40) | HRH3ALDH1A1DRD2DRD4MAPT | |
| SCHEMBL18591772 | 0.76 | SLC6A2 (0.40) | HRH3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | HRH3 3690/4885KDM4E 3116/4885ALDH1A1 2833/4885 |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | HRH3 3605/4885KDM4E 1466/4885ALDH1A1 4291/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | HRH3 3690/4885KDM4E 3116/4885ALDH1A1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.